Clinical trials: Motion Sickness
Motion Sickness
Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in subjects affected by motion sickness during travel
- Trial name
- NCT04327661
- Testing
- Tradipitant
- Where
- 7 sites in United States
- Volunteers
- 366 people
- Sponsor
- Vanda Pharmaceuticals
Motion Sickness
Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness
This multi-site Phase 3 clinical trial is a randomized, double-blind, placebo-controlled and open label active-controlled study to identify the safety and efficacy of a repeated-dose regimen of DPI-386 nasal gel (intranasal…
- Trial name
- NCT04272255
- Testing
- scopolamine HBr, Transdermal Scopolamine
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Repurposed Therapeutics, Inc.
Motion Sickness
Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Safety, Efficacy and Pharmacokinetics of DPI 386 Nasal Gel for the Prevention and Treatment of Nausea Associated with Motion Sickness in Senior Subjects With…
- Trial name
- NCT03988530
- Testing
- Scopolamine
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Repurposed Therapeutics, Inc.
Motion Sickness, Space, Motion Simulation
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
The primary specific aim of this Field Test aim is to evaluate the feasibility and efficacy of administering the intranasal scopolamine gel in operational field settings using both astronaut and ground-control subjects that are…
- Conditions
- Motion Sickness, Space, Motion Simulation, Parabolic Flight
- Trial name
- NCT05852730
- Testing
- DPI-386 Nasal Gel, Other (e.g., promethazine, meclizine)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Repurposed Therapeutics, Inc.
Motion Sickness
Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray
Part 1, the pharmacokinetic (PK) phase, will expand upon the pilot study conducted at Naval Medical Research Laboratory (NAMRL) and has the goal of determining bioavailability and time to Cmax in a larger representative sample.
- Trial name
- NCT02155309
- Testing
- Scopolamine
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Repurposed Therapeutics, Inc.
Motion Sickness
Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness
A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in participants affected by motion sickness during travel
- Trial name
- NCT05903924
- Testing
- Tradipitant
- Where
- 5 sites in United States
- Volunteers
- 316 people
- Sponsor
- Vanda Pharmaceuticals
Motion Sickness
The Prevention and Treatment of Nausea Associated With Motion Sickness
This single-site Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study to identify the safety and efficacy of a repeated-dose regimen of DPI 386 nasal gel (intranasal scopolamine gel) for the prevention…
- Trial name
- NCT03986905
- Testing
- Scopolamine Nasal Gel
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Repurposed Therapeutics, Inc.
Motion Sickness
Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
Randomized, double-blind, placebo-controlled investigating the efficacy of tradipitant in the treatment of motion sickness.
- Trial name
- NCT03772340
- Testing
- Tradipitant
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Vanda Pharmaceuticals
Motion Sickness
Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion
This is a Phase 3, two-arm, randomized, double-blind, placebo-controlled, single dose efficacy and safety study evaluating the use of a nasal gel to prevent nausea and vomiting associated with motion
- Trial name
- NCT04947423
- Testing
- DPI-386 Nasal Gel
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Repurposed Therapeutics, Inc.
Motion Sickness
Levo Phencynonate Hydrochloride for the Prevention of Seasickness
A double-blind, randomized, placebo controlled, multicenter, dose-finding phaseⅡclinical superiority study.
- Trial name
- NCT02241629
- Testing
- levo phencynonate hydrochloride
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
Motion Sickness, Space, Motion Sickness
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
The primary specific aim is to evaluate the use of intranasal scopolamine gel and sensory augmentation as an integrated countermeasure to mitigate motion sickness and enhance sensorimotor performance.
- Conditions
- Motion Sickness, Space, Motion Sickness, Sea Sickness
- Trial name
- NCT05886660
- Testing
- DPI-386 Nasal Gel
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Repurposed Therapeutics, Inc.
Motion Sickness
Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness
Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study to identify the safety, efficacy and pharmacokinetics of a repeated-dose regimen of DPI 386 nasal gel (intranasal scopolamine gel) for the prevention…
- Trial name
- NCT04184115
- Testing
- DPI-386 Nasal Gel
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Repurposed Therapeutics, Inc.
Motion Sickness
A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants.
In this comparative bioavailability and in vivo skin adhesion study, the impact of minor changes in qualitative composition of polyiso-Butylenes (PIB) from a different supplier and change of the manufacturing line of the micro…
- Trial name
- NCT02839135
- Testing
- Reformulated scopolamine patch, Marketed scopolamine patch
- Where
- Canada
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Motion Sickness
DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness
Determine the efficacy, in terms of time to nausea (inclination to vomit), of DPI-386 Nasal Gel as compared to the current standard of care (TDS) and placebo nasal gel.
- Trial name
- NCT04219982
- Testing
- DPI-386 Nasal Gel, Transderm Scop®
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Repurposed Therapeutics, Inc.
Motion Sickness
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
An open label study to investigate the safety and efficacy of tradipitant in participants affected by motion sickness during travel
- Trial name
- NCT06138613
- Testing
- Tradipitant
- Where
- United States
- Volunteers
- 705 people
- Sponsor
- Vanda Pharmaceuticals
Motion Sickness
Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion
This is a Phase 3, randomized, double-blind, placebo-controlled study evaluating DPI-386 Nasal Gel versus placebo. Approximately 500 subjects will be randomized 1:1 (250 DPI 386 Nasal Gel/250 matching Placebo Nasal Gel) are…
- Trial name
- NCT05548270
- Testing
- DPI-386 Nasal Gel
- Where
- United States
- Volunteers
- 503 people, healthy volunteers welcome
- Sponsor
- Repurposed Therapeutics, Inc.